Abstracts tagged "Biologic drugs"

Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting
Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Jaime Calvo-Alen¹, Indalecio Monteagudo², Georgina Salvador Alarcón³, Enrique Raya Álvarez⁴, Loreto Carmona⁵, Luis Cea-Calvo⁶ and Carlos Marras Fernandez-Cid⁷, ¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ²Rheumatology Unit, HGU Gregorio Marañón, Madrid, Madrid, Spain, ³Rheumatology, HU Mutua de Terrassa, Barcelona, Terrassa, Spain, ⁴Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ⁵Instituto de Salud Musculoesquelética, Madrid, Spain, ⁶Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain, ⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain
Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…
Abstract Number: 2540 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Impact of Biologic Use on Disability within a RA Registry
N A Shadick¹, Nicole Gerlanc², M Frits¹, Bradley S. Stolshek³, Brenna Brady², Christine Iannaccone⁴, David Collier⁵, Jing Cui⁶, Alex Mutebi⁷ and Michael Weinblatt⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Health Analytics, LLC, Columbia, MD, ³Amgen, Thousand Oaks, CA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Global Health Economics, Amgen, Thousand Oaks, CA
Background/Purpose: Biologics have become the standard of care for treating moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to small molecule…
Abstract Number: 636 • 2016 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Iñigo Gorostiza¹, Eduardo Úcar Angulo², Catalina Gómez Arango², Clara Eugenia Perez³, Juan Ramon De Dios⁴, Belen Alvarez⁴, Ana Ruibal Escribano^4,5, Claudia Stoye⁴, Margarida Vasques⁴, Joaquin Belzunegui Otano⁶, Antonio Escobar⁷, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Research Department, Hospital Universitario de Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁶Donostia University Hospital, San Sebastian, Spain, ⁷Unidad de Investigación, Red de Investigación en Servicios de Salud en enfermedades crónicas (REDISSEC), Hospital Universitario de Basurto, Bilbao, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain
Background/Purpose: Adalimumab (ADL) dose tapering based on clinical assessment is a usual practice especially in patients who have achieved clinical remission. The primary aim of…
Abstract Number: 2551 • 2016 ACR/ARHP Annual Meeting
Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Jennifer Humphreys¹, Kath Watson², Mark Lunt^2,3, Deborah P.M. Symmons^2,4,5, Kimme L. Hyrich^2,4,6 and the BSRBR-RA, ¹Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Multimorbidity is increasingly prevalent in western populations and has the potential to influence disease specific outcomes. Rheumatoid arthritis (RA) is a chronic inflammatory…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 2617 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Vibeke Strand¹, Namita Tundia², Yan Song³, Dendy Macaulay⁴ and Mahesh Fuldeore⁵, ¹School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Analysis Group, Inc., New York, NY, ⁵AbbVie, Inc, North Chicago, IL
Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This…
Abstract Number: 950 • 2016 ACR/ARHP Annual Meeting
Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Gabriele Simonini¹, Erika Scoccimarro¹, Irene Pontikaki², Giovanna Ferrara³, Teresa Giani¹, Andrea Taddio³, Pier Luigi Meroni⁴ and Rolando Cimaz¹, ¹Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Rheumatology Department, Gaetano Pini Institute, University of Milan, Milano, Italy, ³Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", University of Trieste, Trieste, Italy, ⁴Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy
Background/Purpose: Information regarding the history of patients with JIA after systemic treatment withdrawal would be helpful in driving the choice of duration therapy. While some…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 951 • 2016 ACR/ARHP Annual Meeting
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Bente Glintborg¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Niels Steen Krogh³, Anne Gitte Loft⁴, Jakob Espesen², Jimmi Olsen², Oliver Hendricks⁵, Jolanta Grydehøj², Inger Marie Jensen Hansen², Michael Veedfald Sørensen², Stavros Chrysidis², Birgitte Lange Andersen², Natalia Manilo², Mette Klarlund², Lis Smedegaard Andersen², Henrik Nordin², Salome Kristensen², Jesper Nørregaard² and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark
Background/Purpose: According to national guidelines issued in May 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish…
Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Toshiyuki Watanabe¹, Shinji Fukaya² and Kazumasa Akikawa², ¹3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
Abstract Number: 1004 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster Virus Infection in Patients Treated with Biological Therapies (BIOBADASAR)
Juan Pablo Pirola¹, Soledad Retamozo², Diego Baenas³, Alejandro Alvarellos⁴, Francisco Caeiro⁵, María Celina De La Vega⁶, Gustavo Casado⁷, Gimena Gomez⁸, Javier Roberti⁶, Osvaldo Luis Cerda⁹, Maria de los Angeles Gallardo¹⁰, Ana Quinteros¹¹, Ida Exeni¹², Juan Manuel Bande¹³, Pablo Astesana¹⁴, Analia Alvarez¹⁵, Amelia Granel¹⁶, Alejandra Peluzzon¹⁷, Ana Capuccio¹⁸, Romina Nieto¹⁹, Rossana Quintana²⁰, Eduardo Mussano²¹, Santiago Scarafia²², Carolina Costi²³, Mercedes De La Sota²⁴, Monica Patricia Diaz²⁵, Edson Javier Velozo²⁶, Santiago Aguero²⁷, Cristina Battagliotti²⁸, Sidney Soares de Souza²⁹, Emilia Cavillon³⁰, Analia Bohr³¹, Andrea Smichowski³², Alejandro Benitez³³, Daniela Vidal³⁴, Dora Pereira³⁵, Liliana Martinez³⁶, Luis Somma³⁷, Marta Zalazar³⁸, Pablo Finucci Curi³⁹, Leandro Carlevaris⁴⁰, Guillermo Berbotto⁴¹ and Veronica Saurit¹, ¹Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ³Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁵Reumatología, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁶SAR, CABA, Argentina, ⁷Sociedad Argentina de Reumatologia, CABA, Argentina, ⁸Section of Rheumatology an, SAR, CABA, Argentina, ⁹IREP, CABA, Argentina, ¹⁰Hospital Italiano de Buenos Aires, CABA, Argentina, ¹¹Centro Integral Reumatológico, Tucuman, Argentina, ¹²Sanatorio Parque, Córdoba, Argentina, ¹³Hospital Tornú, CABA, Argentina, ¹⁴Sanatorio Allende, Cordoba, Argentina, ¹⁵Hospital Penna, Bahía Blanca, Argentina, ¹⁶Centro Platense de Reumatología, La Plata, Argentina, ¹⁷Hospital Clínica José de San Martín, CABA, Argentina, ¹⁸Hospital Cesar Milstein, CABA, Argentina, ¹⁹Hospital Provincial, Rosario, Argentina, ²⁰Sanatorio Parque, Rosario, Argentina, ²¹Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, ²²Hospital Bernardino Rivadavia, CABA, Argentina, ²³Hospital San Martín, LaPlata, Argentina, ²⁴Consultorios, Bahia Blanca, Argentina, ²⁵Hospital Zonal Bariloche, Bariloche, Argentina, ²⁶Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁷Sanatorio Pasteur, Catamarca, Argentina, ²⁸Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ²⁹Ramallo 1851, REUMAR, CABA, Argentina, ³⁰Consultorio, Cordoba, Argentina, ³¹Hospital de Rehabilitación Rocca, CABA, Argentina, ³²Atención Integral de Reumatología, CABA, Argentina, ³³CEIM, CABA, Argentina, ³⁴Hospital de Niños de Córdoba, Córdoba, Argentina, ³⁵Centro Raquis, Buenos Aires, Argentina, ³⁶Hospital Fernandez, CABA, Argentina, ³⁷SOMMA, Buenos Aires, Argentina, ³⁸Hospital Pirovano, CABA, Argentina, ³⁹Centro Médico Mitre, Entre Rios, Argentina, ⁴⁰IARI, CABA, Argentina, ⁴¹Sanatorio Británico, Rosario, Argentina
Background/Purpose: Biologic therapies (bDMARDs) have improved the treatment of rheumatic diseases; however, the risk of herpes zoster (HZ) virus infection or reactivation in patients treated…
Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting
Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Cecilie Heegaard Brahe¹, Simon Krabbe², Mikkel Østergaard³, Henrik Rogind⁴, Hanne Slott Jensen³, Annette Hansen⁵, Jesper Nørregaard⁶, Søren Jacobsen⁷, Lene Terslev⁸, Tuan K. Huynh⁹, Dorte Vendelbo Jensen⁵, Natalia Manilo¹⁰, Karsten Heller Asmussen¹¹, Per Brown-Frandsen⁷, Mikael Boesen¹², Zoreh Rastiemadabadi¹³, Daniel Glinatsi¹⁴, Lone Morsel-Carlsen¹⁵, Jakob M. Møller¹⁶, Niels Steen Krogh¹⁷ and Merete Lund Hetland^3,18, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, ¹⁰The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹¹Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, ¹²Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark, ¹³Department of Radiology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁴Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ¹⁵Department of Radiology, Rigshospitalet, Copenhagen, Denmark, ¹⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ¹⁷Zitelab, Frederiksberg, Denmark, ¹⁸Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…
Abstract Number: 1045 • 2016 ACR/ARHP Annual Meeting
2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
Désirée van der Heijde¹, Sofia Ramiro², Robert Landewé³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Alexandre Sepriano², Andrea Regel⁶, John D. Reveille⁷ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: In 2010 the latest ASAS-EULAR recommendations for AS and the ASAS recommendations for the use of TNF-inhibitors (TNFi) have been published. Since then new…
Abstract Number: 3219 • 2016 ACR/ARHP Annual Meeting
Altered microRNA Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals the Pathogenic Profile of These Cells. Effect of Biological Therapies
Nuria Barbarroja¹, Ivan Arias de la Rosa¹, Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Miguel Angel Caracuel-Ruiz³, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras¹, Chary Lopez-Pedrera¹ and Patricia Ruiz-Limon², ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: MicroRNAs (miRNA) have recently emerged as a new class of modulators of gene expression, regulating inflammation, degradation of extracellular matrix and invasive behavior of the…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].